Report Overview:

In this special report, IncreMental Advantage profiles several companies focused on developing new therapies in the field of cardiovascular research. Products in development range from devices to assist in regulating the heart rhythm to replacing cells lost to heart disease. Some companies are developing devices that improve on the current treatments with new technologies, while others have unique devices which, at the current time, have no known marketed counterparts.

This report features interviews with multiple authorities in the biotechnology industry and cardiovascular research.

Interviewees include:

• Richard Linder, President and CEO, Coherex Medical Inc.

• Cesar Diaz, Chairman and CEO, Cardiac Output Technologies

• David Blasczak, Senior V.P and Analyst, Stanford Financial Group

• Marvin Woodall, CEO, Cardiac Research Foundation

• Richard Lundsford, President and CEO, Acorn Cardiovascular

Topics include:

• Adult stem cell use

• Cellular therapy

• Changes in government regulations and policies

• Techniques for closing patent foramen ovale
  

• Addressing problems associated with traditional mechanical valves

• Methods to reduce the need for invasive surgeries